Rockwell Medical announced that the Food and Drug Administration (FDA) has approved Triferic (ferric pyrophosphate citrate) powder packets for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (CKD).
Triferic is a novel iron replacement product delivered to hemodialysis patients via dialysate by replacing the iron loss that occurs during dialysis treatment. Triferic is added to the bicarbonate concentrate and once in dialysate, crosses the dialyzer membrane and enters the blood. It then binds to transferrin and is transported to the erythroid precursor cells to be integrated into hemoglobin. It provides sufficient iron to the bone marrow and maintains hemoglobin without increasing ferritin.
Compared to the current Triferic liquid ampule, the powder packet is smaller, lighter, and is able to contain three times the number of units. Triferic powder packets are expected to launch in the near future.
For more information call (800) 449-3353 or visit Triferic.com.